Virios therapeutics announces submission of final toxicology results to support proposed phase 3 program for novel therapy to treat fibromyalgia

Atlanta, may 15, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”), today announced that it has submitted final toxicology reports as per food & drug administration (“fda”) request as part of their overall review of the company's phase 3 proposal.
VIRI Ratings Summary
VIRI Quant Ranking